Drugs affected by IFNL3
About IFNL3
IFNL3 produces a type III interferon that helps the immune system clear viral infections. A variant in the gene's regulatory region (rs12979860) was, for a long time, the strongest known predictor of who would clear chronic hepatitis C on the old interferon-plus-ribavirin regimen. C/C carriers had roughly double the cure rate of T/T carriers.[1]
Modern direct-acting antiviral (DAA) drugs cure hepatitis C in virtually everyone, so IFNL3 testing is no longer used to choose therapy. It remains historically important and may matter for future immune-related indications.[2]
What we test for IFNL3
Gene2Rx uses definitions covering 2 named IFNL3 alleles, built from 1 variant in Gene2Rx definitions. Results depend on the variants available in your upload.
- Named alleles
- 2
- Defined variants
- 1
- Source
- Gene2Rx definitions
- Genome build
- GRCh38
- Favorable response allele 1
- Unfavorable response allele 1
What do these allele names mean?
IFNL3 alleles are named by the underlying DNA variant rather than a star number. For example, c.61C>T describes a single base change at position 61 of the coding sequence.
DNA variant labels identify sequence differences. Their interpretation depends on the particular gene, the evidence, and the variants that can be assessed in your data. A DNA result does not directly measure enzyme activity.
The source of these definitions is listed above. Missing variants or incomplete coverage can leave a result indeterminate.
Medications with IFNL3 information
This list contains 3 medications with IFNL3 information from the sources shown below. Evidence and report eligibility differ by drug; each page explains its scope and limitations.
Brand products containing a IFNL3-affected ingredient
These branded medications include at least one active ingredient whose metabolism or action involves IFNL3. Each links to its full pharmacogenetic breakdown.
References
- U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling (2024). fda.gov
- PharmGKB / Stanford University. PharmGKB: The Pharmacogenomics Knowledge Base. pharmgkb.org
Explore IFNL3 in your report
Informational only, not medical advice. The presence of a IFNL3 pharmacogenetic guideline does not mean every patient needs to change their dose. Never start, stop, or change a medication without talking to your prescribing clinician.